Healthcare Industry News: ultrasound
News Release - January 16, 2013
Hansen Medical Names Robert Cathcart Senior Vice President of Global SalesMedical Technology Industry Veteran of Nearly 30 Years Has Significant Sales Management Experience in Interventional Cardiology
MOUNTAIN VIEW, CA--(Healthcare Sales & Marketing Network) - Hansen Medical, Inc. ( NASDAQ : HNSN ), a global leader in intravascular robotics, today announced that Robert (Bob) Cathcart has joined the Company in the newly created position of Senior Vice President, Global Sales. Mr. Cathcart will report directly to Bruce Barclay, President and Chief Executive Officer. The creation of this position will allow Hansen Medical to most efficiently execute its global sales strategy.
Mr. Cathcart has nearly 30 years of increasingly senior sales management experience in both domestic and international roles in the medical technology industry with large and small companies. From 2001 to 2009, Mr. Cathcart worked at Datascope Corporation (acquired by Maquet), where he served as the Division President and Vice President of Sales in the Cardiac Assist Division, and later the President of the Interventional Products Division. While leading the Datascope Cardiac Assist Division, Mr. Cathcart led the successful restructuring of the sales organization in 2002, managed a 70 person sales and clinical team and developed a sales training department. During his four year tenure as Division President of Datascope Interventional Products, he helped to launch three new products and drove expansion into Europe and Asia.
"Bob is a strategic leader with extensive commercial and senior management experience in the medical technology industry -- specifically interventional cardiology -- and is a great fit for Hansen Medical," said Bruce Barclay, President and CEO of Hansen Medical. "He has demonstrated success in developing high-performing national and international sales organizations, and delivering growth across multiple product lines, including capital equipment and interventional products. With Bob's global experience and leadership, we will continue to advance our commercial strategy to demonstrate the truly platform-changing capability of intravascular robotics with our Sensei™ and Magellan™ Robotic Systems."
Prior to joining Hansen Medical, Mr. Cathcart served as the Chief Commercial Officer of surgical medical device start-up, HyperBranch Medical Technology, where he was responsible for all sales and marketing in international markets, including Europe, South America and Asia Pacific. Earlier, he served as the President and CEO of FlowCo, Inc./3DT Holdings, a privately-held medical device company focused on interventional cardiology. Mr. Cathcart has also led the sales functions of Promedix Inc., Bard Access Systems and MedChem Products. He began his career at Davis + Geck, where he served as a sales representative, global training manager, regional manager, and eventually area director of the endo-surgery division. He holds a Bachelor of Arts degree from DePauw University.
"As Hansen Medical's commercial momentum continues to grow, I am pleased to be joining the team at such a critical juncture in the Company's development," said Mr. Cathcart. "I believe that Hansen Medical's intravascular robotic technology offers the clinical and economic value increasingly demanded by physicians and hospitals in today's challenging healthcare environment."
About Hansen Medical, Inc.
Hansen Medical, Inc., based in Mountain View, California, is the global leader in intravascular robotics, developing products and technology designed to enable the accurate positioning, manipulation and control of catheters and catheter-based technologies. The Company's Magellan™ Robotic System, NorthStar™ Robotic Catheter and related accessories, which are intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices, have undergone both CE marking and 510(k) clearance and are commercially available in the European Union, and the U.S. In the European Union, the Company's Sensei® X Robotic Catheter System and Artisan Control Catheter are cleared for use during electrophysiology (EP) procedures, such as guiding catheters in the treatment of atrial fibrillation (AF), and the Lynx® Robotic Ablation Catheter is cleared for the treatment of AF. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. In the U.S. the Company's Sensei X Robotic Catheter System and Artisan Control Catheter were cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in EP procedures. In the United States, the Sensei System is not approved for use in guiding ablation procedures; this use remains experimental. The U.S. product labeling therefore provides that the safety and effectiveness of the Sensei X System and Artisan Control Catheter for use with cardiac ablation catheters in the treatment of cardiac arrhythmias, including AF, have not been established. Additional information can be found at www.hansenmedical.com.
This press release contains forward-looking statements regarding, among other things, statements relating to goals, plans, objectives, milestones and future events. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements containing the words "plan," "expects," "potential," "believes," "goal," "estimate," "anticipates," and similar words. These statements are based on the current estimates and assumptions of our management as of the date of this press release and are subject to risks, uncertainties, changes in circumstances and other factors that may cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Examples of such statements include statements about the potential benefits of our technology and the value of our intellectual property portfolio. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others: engineering, regulatory, manufacturing, sales and customer service challenges in developing new products and entering new markets; potential safety and regulatory issues that could slow or suspend our sales; the effect of credit, financial and economic conditions on capital spending by our potential customers; the uncertain timelines for the sales cycle for newly introduced products; the rate of adoption of our systems and the rate of use of our catheters; the scope and validity of intellectual property rights applicable to our products; competition from other companies; our ability to recruit and retain key personnel; our ability to maintain our remedial actions over previously reported material weaknesses in internal controls over financial reporting; our ability to manage expenses and cash flow, and obtain additional financing; and other risks more fully described in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 filed with the SEC on November 9, 2012 and the risks discussed in our other reports filed with the SEC. Given these uncertainties, you should not place undue reliance on the forward-looking statements in this press release. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Hansen Medical, Heart Design (Logo), Hansen Medical (with Heart Design), Sensei and Lynx are registered trademarks, and Magellan and NorthStar are trademarks of Hansen Medical, Inc. in the United States and other countries.
Source: Hansen Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.